Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience

Journal of Emergencies, Trauma and Shock

Volumn 5, Issue 2, 2012, Pages 143-148

  Morel, Nicolas ^a   Chabarttier, Cyrille ^a   Merson, Laurent ^a   Lelias, Agathe ^a   Bernard, Jean Christophe ^a   Delaunay, François ^a   Dabadie, Philippe ^a   Janvier, Gérard ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Haemorrhagic shock; rFVIIa; transfusion; trauma

Indexed keywords

EID: 84862528461     PISSN: 09742700     EISSN: 0974519X     Source Type: Journal    
DOI: 10.4103/0974-2700.96483     Document Type: Article

References (14)

1. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebocontrolled, double-blind clinical trials. J Trauma 2005;59:8-15.
2. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Crit Care 2006;10:R120.
3. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, et al. Epidemiology of trauma deaths: A reassessment. J Trauma 1995;38:185-93.
4. Morel N, Morel O, Chimot L, Lortet V, Julliac B, Lelias A, et al. Acute traumatic haemorrhagic shock and transfusion: What's new in 2009?. Ann Fr Anesth Reanim 2009;28:222-30.
5. Spinella PC, Holcomb JB. Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev 2009;23:231-40.
6. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, et al. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004;57:709-19. (Pubitemid 39431190)
7. Ausset S, Meaudre E, Kaiser E, Sailliol A, Hugard L, Jeandel P. Acute traumatic haemorrhagic shock and transfusion: The French army policy. Ann Fr Anesth Reanim 2009;28:707-9.
8. Spinella PC, Perkins JG, Grathwohl KW, Beekley AC, Holcomb JB. Warm fresh whole blood is independently associated with improved survival for patients with combat-related traumatic injuries. J Trauma 2009;66(4 Suppl):S69-76.
9. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: Implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003;55:886-91. (Pubitemid 38004660)
10. Sapsford W, Watts S, Cooper G, Kirkman E. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig. J Trauma 2007;62:868-79. (Pubitemid 46624203)
11. Durand D GA, Notet V, Hacquard M, Collignon O, Corbonnois G, Plénat F, et al. Efficacy and safety of rFVIIa in a model of hemorrhagic shock in the rabbit. Ann Fr Anesth Reanim 2009;28:S144.
12. Spinella PC, Perkins JG, McLaughlin DF, Niles SE, Grathwohl KW, Beekley AC, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma 2008;64:286-94.
13. McLaughlin DF, Niles SE, Salinas J, Perkins JG, Cox ED, Wade CE, et al. A predictive model for massive transfusion in combat casualty patients. J Trauma 2008;64(2 Suppl):S57-63.
14. Fox CJ, Mehta SG, Cox ED, Kragh JF Jr., Salinas J, Holcomb JB. Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: A case control study. J Trauma 2009;66(4 Suppl):S112-9.